Company / Free Cash Flow
BioRestorative Therapies, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$10.9M
FY2025
5-year range
-$10.9M / -$3.4M
FY2021-FY2025
Trend
-65.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow has fluctuated over the past 10 years, ranging from -$11M in FY2025 to -$3M in FY2021.
Based on SEC 10-K filings.
-$11M in FY2025.
Declined from -$7M to -$11M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow decreased 65.2% year-over-year.
- Peak free cash flow was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -47.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$10.9M | -65.2% |
| FY2024 | -$6.6M | +0.0% |
| FY2023 | -$6.6M | -6.8% |
| FY2022 | -$6.2M | -83.8% |
| FY2021 | -$3.4M | +51.7% |
| FY2020 | -$7.0M | -35.9% |
| FY2019 | -$5.1M | -32.7% |
| FY2018 | -$3.9M | +25.7% |
| FY2017 | -$5.2M | -47.1% |
| FY2016 | -$3.5M | -3.9% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026